Cargando…

Models of depressive pseudoamnestic disorder

OBJECTIVE: Little effort has been made in the past to validate depressive pseudodementia based on hypothesis‐driven approaches. We extended this concept to individuals with amnestic Mild Cognitive Impairment and Major Depression, that is, pseudodepressive amnestic disorder. We tested two hypotheses...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Jongwoo, Lee, Seonjoo, Motter, Jeffrey N., Kim, Hyun, Andrews, Howard, Doraiswamy, P. Murali, Devanand, D. P., Goldberg, Terry E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746884/
https://www.ncbi.nlm.nih.gov/pubmed/36523848
http://dx.doi.org/10.1002/trc2.12335
_version_ 1784849462953246720
author Choi, Jongwoo
Lee, Seonjoo
Motter, Jeffrey N.
Kim, Hyun
Andrews, Howard
Doraiswamy, P. Murali
Devanand, D. P.
Goldberg, Terry E.
author_facet Choi, Jongwoo
Lee, Seonjoo
Motter, Jeffrey N.
Kim, Hyun
Andrews, Howard
Doraiswamy, P. Murali
Devanand, D. P.
Goldberg, Terry E.
author_sort Choi, Jongwoo
collection PubMed
description OBJECTIVE: Little effort has been made in the past to validate depressive pseudodementia based on hypothesis‐driven approaches. We extended this concept to individuals with amnestic Mild Cognitive Impairment and Major Depression, that is, pseudodepressive amnestic disorder. We tested two hypotheses consistent with the presentations and mechanisms associated with this potential syndrome: improvements in cognition would be significantly correlated with improvements in depression after treatment (Hypothesis 1), and if not confirmed, the presence of such an association could be identified once moderator variables were taken into account (Hypothesis 2). METHODS: Within a clinical trial, 61 individuals received open label serotonin reuptake inhibitor (citalopram or venlafaxine) treatment over a 16‐week period. Selective Reminding Test and Hamilton Depression scale were conducted serially to measure change in memory and depression, respectively. Magnetic resonance imaging, other cognitive measures (Alzheimer's Disease Assessment Scale–Cognitive and speed of processing tests), and additional depression measure (Beck Depression Inventory [BDI]) were also administered. RESULTS: No significant associations between improvement in depression and improvement in cognition were observed. Sensitivity analyses with other cognitive measures, the BDI, and exclusion of possible “placebo” responders were negative as well. There were no significant moderation effects for baseline Hamilton Rating Scale for Depression as a measure of symptom severity or age. APOE ε4 genotype and white matter hyperintensity burden yielded counter‐intuitive, albeit marginally significant results. CONCLUSIONS: Negative findings cast doubt on the frequency of depressive pseudoamnestic disorder in older populations with documented depression and memory impairments.
format Online
Article
Text
id pubmed-9746884
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-97468842022-12-14 Models of depressive pseudoamnestic disorder Choi, Jongwoo Lee, Seonjoo Motter, Jeffrey N. Kim, Hyun Andrews, Howard Doraiswamy, P. Murali Devanand, D. P. Goldberg, Terry E. Alzheimers Dement (N Y) Research Articles OBJECTIVE: Little effort has been made in the past to validate depressive pseudodementia based on hypothesis‐driven approaches. We extended this concept to individuals with amnestic Mild Cognitive Impairment and Major Depression, that is, pseudodepressive amnestic disorder. We tested two hypotheses consistent with the presentations and mechanisms associated with this potential syndrome: improvements in cognition would be significantly correlated with improvements in depression after treatment (Hypothesis 1), and if not confirmed, the presence of such an association could be identified once moderator variables were taken into account (Hypothesis 2). METHODS: Within a clinical trial, 61 individuals received open label serotonin reuptake inhibitor (citalopram or venlafaxine) treatment over a 16‐week period. Selective Reminding Test and Hamilton Depression scale were conducted serially to measure change in memory and depression, respectively. Magnetic resonance imaging, other cognitive measures (Alzheimer's Disease Assessment Scale–Cognitive and speed of processing tests), and additional depression measure (Beck Depression Inventory [BDI]) were also administered. RESULTS: No significant associations between improvement in depression and improvement in cognition were observed. Sensitivity analyses with other cognitive measures, the BDI, and exclusion of possible “placebo” responders were negative as well. There were no significant moderation effects for baseline Hamilton Rating Scale for Depression as a measure of symptom severity or age. APOE ε4 genotype and white matter hyperintensity burden yielded counter‐intuitive, albeit marginally significant results. CONCLUSIONS: Negative findings cast doubt on the frequency of depressive pseudoamnestic disorder in older populations with documented depression and memory impairments. John Wiley and Sons Inc. 2022-12-13 /pmc/articles/PMC9746884/ /pubmed/36523848 http://dx.doi.org/10.1002/trc2.12335 Text en © 2022 The Authors. Alzheimer's & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals LLC on behalf of Alzheimer's Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Choi, Jongwoo
Lee, Seonjoo
Motter, Jeffrey N.
Kim, Hyun
Andrews, Howard
Doraiswamy, P. Murali
Devanand, D. P.
Goldberg, Terry E.
Models of depressive pseudoamnestic disorder
title Models of depressive pseudoamnestic disorder
title_full Models of depressive pseudoamnestic disorder
title_fullStr Models of depressive pseudoamnestic disorder
title_full_unstemmed Models of depressive pseudoamnestic disorder
title_short Models of depressive pseudoamnestic disorder
title_sort models of depressive pseudoamnestic disorder
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746884/
https://www.ncbi.nlm.nih.gov/pubmed/36523848
http://dx.doi.org/10.1002/trc2.12335
work_keys_str_mv AT choijongwoo modelsofdepressivepseudoamnesticdisorder
AT leeseonjoo modelsofdepressivepseudoamnesticdisorder
AT motterjeffreyn modelsofdepressivepseudoamnesticdisorder
AT kimhyun modelsofdepressivepseudoamnesticdisorder
AT andrewshoward modelsofdepressivepseudoamnesticdisorder
AT doraiswamypmurali modelsofdepressivepseudoamnesticdisorder
AT devananddp modelsofdepressivepseudoamnesticdisorder
AT goldbergterrye modelsofdepressivepseudoamnesticdisorder